A Cross-Sectional Study on The Prevalence of Anemia in Maintenance Hemodialysis and Peritoneal Dialysis Patients and Its Related Factors

Abstract

Objective: To study the prevalence of anemia, the proportion of hemoglobin (Hb) levels, the treatment methods, and the influencing factors of Hb levels in maintenance hemodialysis (MHD) and peritoneal dialysis patients. Methods: In this study, 602 patients with maintenance hemodialysis and continuous ambulatory peritoneal dialysis were enrolled from December 2020 to December 2022 in our hospital, and their medical records were collected and summarized. The main contents included the patient’s gender, age, primary disease, dialysis duration, dialysis method, the use of erythropoietic stimulating agents (ESA), intravenous iron, and laboratory tests. A Hb index exceeding 110 g/L was set as the standard for the prevalence of anemia. Results: The rate of anemia in patients undergoing blood purification was 83%. The proportion of ESA use was 84.1%, and the proportion of iron use was 76.7%, of which the proportion of intravenous iron used was 17.0%, and the proportion of folic acid used was 28.3%. Conclusion: The incidence of anemia in MHD patients was relatively high, with a low proportion of patients reaching the standard Hb levels. Risk factors include albumin (ALB) levels, iron storage, white blood cells, C-reactive protein, cholesterol, etc. Nutritional support, iron supplementation, and prevention of micro-inflammatory reactions can effectively promote the improvement of Hb indicators in dialysis patients to prevent anemia.